Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL3789572 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9751837 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1443661 | 0.93 | SLC7A5 (0.75) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1443654 | 0.93 | SLC7A5 (0.75) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8937062 | 0.91 | SLC7A5 (0.53) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8937070 | 0.91 | SLC7A5 (0.53) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL16820324 | 0.90 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27742384 | 0.89 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL6378175 | 0.89 | SLC7A5 (0.73) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL5707691 | 0.89 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496245-B1 | ANALOGS OF PITUTARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | UNIV TULANE (US) | 2016-07-20 | — | — | EP | disclosed |
| US-8916517-B2 | Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130065816-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-03-14 | — | — | US | disclosed |
| US-20110312877-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | APARNA BIOSCEIENCES (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2257280-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | Aparna Biosciences (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108822-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | APARNA BIOSCIENCES (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312877-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | TLR3, CHIA, TSG101 | SLC7A5 3132/4885PTGS1 998/4885ALPI 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.